Comparison of lansoprazole (30 mg) and omeprazole (20 mg) in the treatment of duodenal ulcer. a multicenter double-blind comparative trial
Petite, J.P.; Slama, J.L.; Licht, H.; Lemerez, M.; Coste, T.; Andrieu, J.; Grimaud, J.C.; Julien, H.; Dupuis, J.; Sallerin, V.
Gastroenterologie Clinique et Biologique 17(5): 334-340
1993
ISSN/ISBN: 0399-8320 PMID: 8349067 Document Number: 417354
The efficacy of lansoprazole (30 mg/d) and omeprazole (20 mg/d) has been assessed in active duodenal ulcer disease in 144 patients included in a multicentric, randomized, double-blind trial. After two weeks, the healing rates were 74% and 58% in the lansoprazole and omeprazole groups, respectively (P = 0.049). After 4 weeks, the healing rates were 94% in each group (NS). The delay to pain relief was 2 days for lansoprazole and 3 days for omeprazole (NS). Minor side effects occurred in 12% of the lansoprazole treated patients and in 13% of the omeprazole treated patients. No severe adverse events were reported. A slight increase in serum gastrin level was observed, similar in both groups (+35 UI/L and +19 UI/L for lansoprazole and omeprazole respectively). This study confirms previous results concerning the efficacy of both treatments in duodenal ulcer disease. The statistical difference observed for healing rates after 2 weeks could correspond to a faster efficacy for lansoprazole (30 mg) than for omeprazole (20 mg).